HOME >> BIOLOGY >> NEWS
Mouse FH knockout resembles human renal cell cancer

A new mouse model is providing valuable insight into the biochemical pathways that are associated with development of renal cysts and renal cell cancer. The research, published in the April issue of the journal Cancer Cell, published by Cell Press, provides new information about the relationship between hypoxia and cancer progression. In addition, it is likely that this mouse model may prove to be a useful tool for testing therapeutic strategies for renal cell cancer.

Mutations in the Krebs cycle enzyme fumarate hydratase (FH) tumor suppressor gene are present in individuals with renal cysts and renal cell cancer (HLRCC). These mutations are also linked to overexpression of hypoxia-inducible factor (HIF), a transcription factor that is activated when cells are exposed to an environment that is deficient in oxygen. In order to provide a model of HLRCC as well as to further examine the role of Krebs cycle dysfunction in cancer initiation and progression, Dr. Patrick J. Pollard from the Molecular and Population Genetics Laboratory at the London Research Institute and colleagues created a kidney-specific Fh1-deficient mouse model.

The researchers observed that, like humans, the Fh1-deficient mice developed clonal and proliferative renal cysts that exhibited a characteristic overexpression of HIF. The animals eventually succumbed to renal failure. Additional studies went on to show that Fh1 inactivation in mouse embryonic stem cells leads to upregulated HIF. The researchers propose that activation of the hypoxia pathway is likely to be the cause of the cysts in the mice and that if the cysts had not caused renal failure, progression to malignancy may have occurred.

Results from these studies demonstrate that inactivation of FH in the kidney causes activation of the hypoxia pathway and formation of numerous cysts. The researchers conclude that FH deficiency is a direct cause of the increased HIF expression observed in HLRCC tumors and tha
'"/>

Contact: Erin Doonan
edoonan@cell.com
617-397-2802
Cell Press
9-Apr-2007


Page: 1 2

Related biology news :

1. Mouse model advances understanding of synovial sarcoma
2. Mouse stem cell line advance suggests potential for IVF-incompetent eggs
3. Mouse model underestimates the critical role of Tyk2 in human immune system
4. Mouse DNA to aid biomedical research
5. Mouse strain with gene stutter will help leukemia research
6. Knockout Mouse Project
7. NIH launches Knockout Mouse Project
8. Mouse mimics chronic leukemia, will aid drug development
9. Mouse, frog and bird put Snail and Slug to different uses
10. Mouse study reveals human X-SCID gene therapy poses substantial cancer risk
11. Mouse to man: The story of chromosomes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
Breaking Biology Technology:
Cached News: